Sign in

You're signed outSign in or to get full access.

Macae Etoch

**Senior Research Associate** and analyst at Stephens

Mac Etoch is a **Senior Research Associate** and analyst at Stephens Inc., specializing in the life science tools and pharma services sector. Specific companies covered and performance metrics are not detailed in available sources, though he has engaged with company executives on topics like restructuring charges and operational progress. Etoch holds a Master of Finance from Southern Methodist University’s Cox School of Business and a B.S.B.A. in Finance with minors in Biology and Management from the University of Arkansas; he is also a CFA charterholder. Career timeline and previous firm experience are not specified in the sources reviewed.

Macae Etoch's questions to BIOLIFE SOLUTIONS (BLFS) leadership

Question · Q4 2025

Macae Etoch asked about the recently announced partnership agreement with Qkine Limited, specifically regarding the adoption potential of their cytokine products when packaged with BioLife's CellSeal vials, and inquired about the expected margin profile for this new business segment.

Answer

Chairman and CEO Roderick de Greef stated that the development project to combine Qkine's cytokines with CellSeal vials is expected to take 6-9 months, with significant revenue pull-through anticipated late 2026 or early 2027. He emphasized that this is a long-term strategic move rather than a driver for immediate 2026 revenue, and declined to disclose specific margin profiles for competitive reasons.

Ask follow-up questions

Fintool

Fintool can predict BIOLIFE SOLUTIONS logo BLFS's earnings beat/miss a week before the call